The Alzheimer’s Association International Conference 2017 (AAIC17) took place in London from 16 to 20 July.
On Monday 17, Professor José María Frade presented in Poster format part o the results that endorse the research work that is being carried out by Tetraneuron with the objetive of developing a Therapy and an Early Biomarker for Alzheimer’s Desease.
Tetraneuron’s solution against that disease is based on a radically different aproach, focused in slowing the disease at the early stages, when senile plaques have not been developed yet and no other symptoms of the disease are evident.
Este sitio web utiliza cookies para que usted tenga la mejor experiencia de usuario. Si continúa navegando está dando su consentimiento para la aceptación de las mencionadas cookies y la aceptación de nuestra política de cookies, pinche el enlace para mayor información.plugin cookies
ACEPTAR